Navigation Links
A fly mutation suggests a new route for tackling ALS
Date:4/8/2013

researchers discovered a mutation in the mouse, called Wlds, which enables a damaged axon to survive for weeks after injury. "That fundamentally changed how we think about an axon. Under certain circumstances, axons can survive for a much longer time than we have given them credit for," Dr. Freeman explained.

Freeman's laboratory speculated that if axon self-destruction is an active process, then there should be genes in the fly genome whose normal function is to destroy cut axons. They decided if they could break those genes responsible for axon destruction, then the axons shouldn't fall apart. To identify those genes, they performed a labor-intensive screen, randomly breaking genes in the fly genome and looking for those that when broken blocked axon destruction after injury.

This approach led to the identification of one gene, called dSarm, whose normal function is to promote the destruction of the axon after injury. "We got beautiful protection of axons when we knocked out this molecule," Dr. Freeman said. Mice and humans have forms of this gene too, and Freeman and colleagues have shown its functions in a similar way in mice. The preservation of these signaling mechanisms from flies to humans is a sign of evolutionary retention and argues for its importance.

To get closer to applying the axon death gene to the study of disease, the researchers crossed the mouse version of the Sarm mutation into a mouse model that has a type of familial ALS, which is also in humans. Although the mice still lost weight and had difficulty with a mobility test, they lived about 10 days longer than their brethren without the Sarm mutation, and at least half of their motor neurons remained intact. "Since not all the motor neurons are needed," Dr. Freeman said, "even with a 50 percent reduction a patient could feel very close to normal. It would be life-changing for the patient, so it's a step in the right direction."

"We used Wallerian dege
'/>"/>

Contact: Phyllis Edelman
pedelman@genetics-gsa.org
301-634-7302
Genetics Society of America
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Shedding light on a gene mutation that causes signs of premature aging
2. Bird flu mutation study offers vaccine clue
3. One gene, many mutations
4. Found a genetic mutation causing mental retardation very similar to Angelman syndrome in Amish
5. Sleator lab identifies single point mutation in Listeria monocytogenes
6. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
7. Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals
8. Research discovers gene mutation causing rare eye disease
9. Animal model of human evolution indicates thick hair mutation emerged 30,000 years ago
10. Consumers have few negative reactions to the results of genetic testing for cancer mutations
11. Mitochondrial mutations: When the cells 2 genomes collide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... than 200 million years ago, a massive extinction decimated ... end of the Triassic period and the onset of ... dinosaurs to dominate Earth for the next 135 million ... marine and terrestrial species. It,s not entirely clear ...
... gentler chemotherapy drug in the form of nanoparticles has been designed ... woman,s fertility but extra tough on cancer. This is the first ... using a novel in vitro test. ... that predicts the toxicity of a chemotherapy drug to fertility and ...
... WASHINGTON, D.C.--Pit latrines are one of the most common ... on the rise as countries aim to meet the ... evidence supports the use of these basic toilets as ... pit latrines can actually allow disease-causing microbes or other ...
Cached Biology News:Huge and widespread volcanic eruptions triggered the end-Triassic extinction 2Huge and widespread volcanic eruptions triggered the end-Triassic extinction 3Huge and widespread volcanic eruptions triggered the end-Triassic extinction 4New chemo drug gentler on fertility, tougher on cancer 2New chemo drug gentler on fertility, tougher on cancer 3Additional research must be done to ensure safety of pit latrines, new study says 2
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... WARSAW, Ind., Sept. 15 Symmetry Medical Inc.,(NYSE: ... the global,orthopedic device industry and other medical markets, announced ... is scheduled to,present at the UBS Global Life Sciences ... City on Thursday, September 25, 2008 at 11:30 a.m. ...
... Corporation,(OTC Bulletin Board: CONX), a worldwide developer and ... call on Thursday, September,25, 2008, at 4:00 PM ... for its fiscal year ended June 30, 2008, ... marketing activities., Corgenix invites all those interested ...
... 15 Epeius Biotechnologies,Corporation today announced that Rexin-G, ... been highlighted in a recent NEWS article,published by ... Sept. 9,2008). The article, authored by Vickie Brower, ... that may succeed where small,molecules and proteins have ...
Cached Biology Technology:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
Biology Products: